共 46 条
[1]
Villa F(2019)Determinants of price negotiations for new drugs. The experience of the Italian Medicine Agency Health Policy 123 595-600
[2]
Tutone M(2004)Grading quality of evidence and strength of recommendations BMJ 328 1490-38
[3]
Altamura G(2019)How medicines are used in Italy: data from the national report 2018 Heal Policy Technol 9 32-10
[4]
Atkins D(2018)Accesso precoce al mercato: dalle approvazioni condizionate di EMA agli accordi negoziali particolari di AIFA GRHTA 2018 1-247
[5]
Best D(2013)Multi-tier drugs assessment in a decentralised health care system: the Italian case-study Health Policy 112 241-122
[6]
Briss PA(2017)Recommendations from the European working group for value assessment and funding processes in rare diseases (ORPH-VAL) Orphanet J Rare Dis 12 50-105
[7]
Cangini A(2012)Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis 26 74-1282
[8]
Trotta F(2010)Orphan drugs: relating price determination to disease prevalence BMJ 341 c4615-undefined
[9]
Mammarella F(2019)PMU45—prevalence vs. treatment cost: analysis of drugs for rare disease in Italy Value Health 22 S716-undefined
[10]
Villa F(2017)Determinants of orphan drugs prices in France: a regression analysis Orphanet J Rare Dis 12 75-undefined